Bysanti (Milsaperidone)

Bysanti (milsaperidone) is an atypical antipsychotic indicated for:

• Treatment of schizophrenia in adults.
• Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults

Recommended Dosage:
The recommended dosage of Bysanti is administered orally twice daily, with or without food, as directed by the prescribing physician. Start treatment at a low dose and gradually titrate based on individual patient tolerability and clinical response to minimize the risk of orthostatic hypotension. Dose adjustments should be made cautiously, with close monitoring of blood pressure, particularly during the initial titration phase.
If treatment is interrupted for a significant period, re-initiate therapy at a lower dose and re-titrate as clinically appropriate. In patients experiencing adverse reactions, consider dose reduction or temporary interruption until symptoms improve. Continue treatment as long as clinical benefit is observed and therapy is tolerated.

• Elderly patients with dementia-related psychosis treated with antipsychotic medicines have an increased risk of death. Most deaths are related to heart problems or infections. Bysanti is not approved for use in elderly patients with dementia-related psychosis.
• Elderly patients with dementia-related psychosis may have a higher risk of stroke and mini-stroke when treated with antipsychotics. Monitor for sudden weakness, confusion, or speech difficulty. Stop treatment in case cerebrovascular events are suspected or confirmed.
• Treatment with Bysanti may prolong the QTc interval, which can increase the risk of serious heart rhythm problems. Do not use the drug in patients with known heart conditions or those taking other QT-prolonging drugs. Monitor ECG and electrolytes when clinically necessary.
• Neuroleptic malignant syndrome is a rare but serious condition with symptoms such as muscle stiffness, high fever, confusion, and unstable vital signs. Stop treatment promptly if suspected and provide urgent medical treatment and supportive care.
• Long-term use of antipsychotics like Bysanti may cause tardive dyskinesia, a condition involving uncontrolled movements of the face or body. Risk increases with the duration of treatment. Reduce the dose or discontinue if symptoms appear.
• This medicinal product may cause metabolic changes, including weight gain, increased blood sugar, and changes in cholesterol levels. Monitor weight, glucose, and lipid profile regularly. Patients with diabetes or risk factors should be carefully observed during treatment.
• Bysanti therapy may cause a drop in blood pressure when standing, leading to dizziness or fainting. This risk is higher during treatment initiation or dose changes. Advise patients to rise slowly and monitor blood pressure regularly.
• Bysanti may increase the risk of falls due to dizziness, sedation, or low blood pressure. Assess fall risk, especially in elderly patients. Implement preventive measures to reduce injury, particularly in those with mobility or balance issues.
• Use Bysanti with caution in patients with a history of seizures or conditions that lower the seizure threshold. Monitor patients closely and consider dose adjustments if seizures occur during treatment.
• Antipsychotics like Bysanti may cause difficulty in swallowing, which can increase the risk of choking or aspiration. Monitor patients with swallowing problems closely, especially elderly individuals or those with neurological conditions.
• Bysanti may rarely cause priapism, a prolonged and painful erection unrelated to sexual activity. This condition requires immediate medical attention to prevent permanent damage. Advise patients to seek urgent care if symptoms occur.
• There are limited data on the use of this medicine during pregnancy. Antipsychotic use in late pregnancy may cause symptoms in newborns, such as agitation or breathing difficulties. Use only if the benefits outweigh the risks and consult a healthcare provider.
• It is unknown whether Bysanti passes into human breast milk. Because of potential risks to the infant, breastfeeding is not recommended during treatment. Discuss benefits and risks with a healthcare provider before continuing breastfeeding.

What documents are required to import BYSANTI® to India?

BYSANTI (milsaperidone) tablets may be imported by patients or government hospitals in the patients’ names only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is BYSANTI® available in India?

BYSANTI (milsaperidone tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) facilitates the import of cancer medicines under named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Bysanti in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Bysanti price in India.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

BYSANTI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of BYSANTI (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact us at WhatsApp: +91 98104 69557 | Toll-Free Number: 1800-1200-365 or write us at info@indianpharmanetwork.in for Bysanti cost in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source BYSANTI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Bysanti®?

Milsaperidone is the Generic Name for the trade name drug Bysanti®.

What is the Manufacturer’s Name of Bysanti®?

Bysanti® is manufactured by Vanda Pharmaceuticals Inc.

Is Bysanti® approved by the FDA?

Yes. Bysanti® is approved by the FDA. Date of first approval: February 20, 2026.

What strengths and dosage forms are available for Bysanti®?

Bysanti® is available as Tablets: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg for oral administration.

What are the most common side effects of Bysanti® Tablets?

• Schizophrenia: nasal congestion, dizziness, dry mouth, fatigue, tachycardia, orthostatic hypotension, somnolence, and increased weight.
• Bipolar mania: dry mouth, tachycardia, dizziness, increased hepatic enzymes, nasal congestion, increased weight, hypotension, and somnolence.

How does Bysanti Import in India work?

Bysanti Import in India is possible through the Named Patient Program. This means the medicine can be imported for a specific patient with a valid doctor’s prescription. Indian Pharma Network helps manage the complete process, including approvals and delivery, making sure the medicine reaches the patient safely and legally.

Who is a reliable Bysanti supplier in India?

Indian Pharma Network is a trusted Bysanti supplier in India, facilitating compliant access through global sourcing channels and structured documentation support for eligible patients under applicable regulatory provisions.

How much does Bysanti® Tablet cost in India?

Bysanti® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Bysanti prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Bysanti cost in India, please call/WhatsApp +91 98104 69557 or send an email to info@indianpharmanetwork.in.

Can Bysanti® Tablets be available in SAARC countries?

Apart from Gulf countries, Bysanti® Tablets can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Bysanti® Tablets in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Bysanti® Tablets online in India?

Yes, one can buy Bysanti in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the supply of Bysanti® Tablets through legal channels.

Who is an authorized Bysanti importer in India?

Indian Pharma Network acts as a Bysanti importer in India, assisting with Named Patient Import processes, regulatory documentation, and compliant international procurement for patients requiring this therapy.

What are the storage conditions of Bysanti® Tablets?

Store the tablets at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30 °C (59°F to 86°F). Protect the tablets from exposure to light and moisture.